Features

The opportunities to bring in new money for non-face-to-face services are encouraging, but the requirements present obstacles.

Spontaneous coronary artery dissection is emerging from the shadows as an important cause of myocardial infarction in younger women. That visibility is leading to fundamental changes in how the condition is diagnosed and treated.

Sanjaya Gupta, MD, MBA, details how his practice is leverage wearables as a patient engagement tool.

Sometimes a move in the right direction starts with a good hard look in the rearview mirror, then breaking it off to start anew with greater wisdom.

Cardiologists discuss the questions and concerns swirling around the thriving wearables market as patients strap on a variety of smart devices and expect their physicians to catch up.

Atrial fibrillation patients with coronary artery disease pose a delicate balancing act for physicians. A growing awareness of bleeding vs. ischemic risks could soon lead to a steadier therapeutic response.

Where I live in Pennsylvania, not far from the “Heroin Highway,” the local news delivers frequent but superficial glimpses of the impact of the opioid epidemic on families and our communities. Statistics underscore such stories: More than 70,000 drug over-dose deaths just in 2017 with an associated “economic burden” exceeding $78 billion per year. 

As rates of infective endocarditis among intravenous drug users skyrocket, cardiologists are finding that treating the heart condition without addressing the disease of addiction contributes to readmissions and mortality. 

Earning approval to use a new cardiovascular drug in the clinical setting can cost 100+ times the average of bringing other medications to market.  

Telehealth enthusiasts are optimistic about telestenting’s potential to solve access-to-care issues but concede that significant obstacles must be overcome before it will be ready for prime time.

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR. 

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist.